{
    "clinical_study": {
        "@rank": "151288", 
        "arm_group": [
            {
                "arm_group_label": "SPD489 Low Dose Range", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "SPD489 High Dose Range", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary purpose of this study is to determine whether  SPD489 low dose range (40, 80, or\n      100mg) and high dose range (120, 140, or 160mg) are effective in the treatment of Negative\n      Symptoms."
        }, 
        "brief_title": "SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "B1", 
                            "description": "SPD489 low dose range (40mg, 80mg, and 100mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once-daily for 4 weeks; then,\n100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;\nif able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks", 
                            "title": "SPD489 Low Dose Range"
                        }, 
                        {
                            "@group_id": "B2", 
                            "description": "SPD489 high dose range (120mg, 140mg and 160mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once daily for 1 week; then\n120 mg capsule once-daily for 1 week, then,\n140 mg capsule once-daily for 2 weeks, then\n160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;\nif able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks", 
                            "title": "SPD489 High Dose Range"
                        }, 
                        {
                            "@group_id": "B3", 
                            "description": "Placebo: One capsule a day for 26 weeks", 
                            "title": "Placebo"
                        }, 
                        {
                            "@group_id": "B4", 
                            "description": "Total of all reporting groups", 
                            "title": "Total"
                        }
                    ]
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@value": "0"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@value": "0"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@value": "0"
                                            }, 
                                            {
                                                "@group_id": "B4", 
                                                "@value": "0"
                                            }
                                        ]
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1"
                                                }, 
                                                {
                                                    "@group_id": "B2"
                                                }, 
                                                {
                                                    "@group_id": "B3"
                                                }, 
                                                {
                                                    "@group_id": "B4"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "<=18 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1"
                                                }, 
                                                {
                                                    "@group_id": "B2"
                                                }, 
                                                {
                                                    "@group_id": "B3"
                                                }, 
                                                {
                                                    "@group_id": "B4"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Between 18 and 65 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1"
                                                }, 
                                                {
                                                    "@group_id": "B2"
                                                }, 
                                                {
                                                    "@group_id": "B3"
                                                }, 
                                                {
                                                    "@group_id": "B4"
                                                }
                                            ]
                                        }, 
                                        "sub_title": ">=65 years"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Age", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1"
                                                }, 
                                                {
                                                    "@group_id": "B2"
                                                }, 
                                                {
                                                    "@group_id": "B3"
                                                }, 
                                                {
                                                    "@group_id": "B4"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1"
                                                }, 
                                                {
                                                    "@group_id": "B2"
                                                }, 
                                                {
                                                    "@group_id": "B3"
                                                }, 
                                                {
                                                    "@group_id": "B4"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1"
                                            }, 
                                            {
                                                "@group_id": "B2"
                                            }, 
                                            {
                                                "@group_id": "B3"
                                            }, 
                                            {
                                                "@group_id": "B4"
                                            }
                                        ]
                                    }, 
                                    "sub_title": "United States"
                                }
                            }, 
                            "param": "Number", 
                            "title": "Region of Enrollment", 
                            "units": "participants"
                        }
                    ]
                }, 
                "population": "Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized"
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually."
            }, 
            "limitations_and_caveats": "Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized", 
            "outcome_list": {
                "outcome": [
                    {
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "SPD489 low dose range (40mg, 80mg, and 100mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once-daily for 4 weeks; then,\n100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;\nif able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 Low Dose Range"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "SPD489 high dose range (120mg, 140mg and 160mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once daily for 1 week; then\n120 mg capsule once-daily for 1 week, then,\n140 mg capsule once-daily for 2 weeks, then\n160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;\nif able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 High Dose Range"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Placebo: One capsule a day for 26 weeks", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1"
                                                    }, 
                                                    {
                                                        "@group_id": "O2"
                                                    }, 
                                                    {
                                                        "@group_id": "O3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "title": "Change From Baseline in Negative Symptom Assessment (NSA-16) Total Score at 26 Weeks"
                                }
                            ]
                        }, 
                        "population": "Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and 26 weeks", 
                        "title": "Change From Baseline in Negative Symptom Assessment (NSA-16) Total Score at 26 Weeks", 
                        "type": "Primary"
                    }, 
                    {
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "SPD489 low dose range (40mg, 80mg, and 100mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once-daily for 4 weeks; then,\n100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;\nif able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 Low Dose Range"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "SPD489 high dose range (120mg, 140mg and 160mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once daily for 1 week; then\n120 mg capsule once-daily for 1 week, then,\n140 mg capsule once-daily for 2 weeks, then\n160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;\nif able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 High Dose Range"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Placebo: One capsule a day for 26 weeks", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1"
                                                    }, 
                                                    {
                                                        "@group_id": "O2"
                                                    }, 
                                                    {
                                                        "@group_id": "O3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "title": "Change From Baseline in the Personal and Social Performance (PSP) Scale Score at 26 Weeks"
                                }
                            ]
                        }, 
                        "population": "Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and 26 weeks", 
                        "title": "Change From Baseline in the Personal and Social Performance (PSP) Scale Score at 26 Weeks", 
                        "type": "Secondary"
                    }, 
                    {
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "SPD489 low dose range (40mg, 80mg, and 100mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once-daily for 4 weeks; then,\n100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;\nif able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 Low Dose Range"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "SPD489 high dose range (120mg, 140mg and 160mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once daily for 1 week; then\n120 mg capsule once-daily for 1 week, then,\n140 mg capsule once-daily for 2 weeks, then\n160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;\nif able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 High Dose Range"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Placebo: One capsule a day for 26 weeks", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1"
                                                    }, 
                                                    {
                                                        "@group_id": "O2"
                                                    }, 
                                                    {
                                                        "@group_id": "O3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "title": "Change From Baseline in Simpson Angus Scale (SAS) Total Score at 26 Weeks"
                                }
                            ]
                        }, 
                        "population": "Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized", 
                        "safety_issue": "Yes", 
                        "time_frame": "Baseline and 26 weeks", 
                        "title": "Change From Baseline in Simpson Angus Scale (SAS) Total Score at 26 Weeks", 
                        "type": "Secondary"
                    }, 
                    {
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "SPD489 low dose range (40mg, 80mg, and 100mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once-daily for 4 weeks; then,\n100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;\nif able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 Low Dose Range"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "SPD489 high dose range (120mg, 140mg and 160mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once daily for 1 week; then\n120 mg capsule once-daily for 1 week, then,\n140 mg capsule once-daily for 2 weeks, then\n160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;\nif able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 High Dose Range"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Placebo: One capsule a day for 26 weeks", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1"
                                                    }, 
                                                    {
                                                        "@group_id": "O2"
                                                    }, 
                                                    {
                                                        "@group_id": "O3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "title": "Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at 26 Weeks"
                                }
                            ]
                        }, 
                        "population": "Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized", 
                        "safety_issue": "Yes", 
                        "time_frame": "Baseline and 26 weeks", 
                        "title": "Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at 26 Weeks", 
                        "type": "Secondary"
                    }, 
                    {
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "SPD489 low dose range (40mg, 80mg, and 100mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once-daily for 4 weeks; then,\n100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;\nif able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 Low Dose Range"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "SPD489 high dose range (120mg, 140mg and 160mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once daily for 1 week; then\n120 mg capsule once-daily for 1 week, then,\n140 mg capsule once-daily for 2 weeks, then\n160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;\nif able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 High Dose Range"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Placebo: One capsule a day for 26 weeks", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1"
                                                    }, 
                                                    {
                                                        "@group_id": "O2"
                                                    }, 
                                                    {
                                                        "@group_id": "O3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "title": "Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) at 26 Weeks"
                                }
                            ]
                        }, 
                        "population": "Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized", 
                        "safety_issue": "Yes", 
                        "time_frame": "Baseline and 26 weeks", 
                        "title": "Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) at 26 Weeks", 
                        "type": "Secondary"
                    }, 
                    {
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "SPD489 low dose range (40mg, 80mg, and 100mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once-daily for 4 weeks; then,\n100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;\nif able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 Low Dose Range"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "SPD489 high dose range (120mg, 140mg and 160mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once daily for 1 week; then\n120 mg capsule once-daily for 1 week, then,\n140 mg capsule once-daily for 2 weeks, then\n160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;\nif able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 High Dose Range"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Placebo: One capsule a day for 26 weeks", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1"
                                                    }, 
                                                    {
                                                        "@group_id": "O2"
                                                    }, 
                                                    {
                                                        "@group_id": "O3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "title": "Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at 26 Weeks"
                                }
                            ]
                        }, 
                        "population": "Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and 26 weeks", 
                        "title": "Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at 26 Weeks", 
                        "type": "Secondary"
                    }, 
                    {
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "SPD489 low dose range (40mg, 80mg, and 100mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once-daily for 4 weeks; then,\n100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;\nif able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 Low Dose Range"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "SPD489 high dose range (120mg, 140mg and 160mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once daily for 1 week; then\n120 mg capsule once-daily for 1 week, then,\n140 mg capsule once-daily for 2 weeks, then\n160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;\nif able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 High Dose Range"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Placebo: One capsule a day for 26 weeks", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1"
                                                    }, 
                                                    {
                                                        "@group_id": "O2"
                                                    }, 
                                                    {
                                                        "@group_id": "O3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "title": "Change From Baseline in Cognitive Test Battery (CogState Battery) Score at 26 Weeks"
                                }
                            ]
                        }, 
                        "population": "Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and 26 weeks", 
                        "title": "Change From Baseline in Cognitive Test Battery (CogState Battery) Score at 26 Weeks", 
                        "type": "Secondary"
                    }, 
                    {
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "SPD489 low dose range (40mg, 80mg, and 100mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once-daily for 4 weeks; then,\n100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;\nif able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 Low Dose Range"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "SPD489 high dose range (120mg, 140mg and 160mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once daily for 1 week; then\n120 mg capsule once-daily for 1 week, then,\n140 mg capsule once-daily for 2 weeks, then\n160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;\nif able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 High Dose Range"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Placebo: One capsule a day for 26 weeks", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1"
                                                    }, 
                                                    {
                                                        "@group_id": "O2"
                                                    }, 
                                                    {
                                                        "@group_id": "O3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "title": "Change From Baseline in Social Functioning Scale (SFS) at 26 Weeks"
                                }
                            ]
                        }, 
                        "population": "Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and 26 weeks", 
                        "title": "Change From Baseline in Social Functioning Scale (SFS) at 26 Weeks", 
                        "type": "Secondary"
                    }, 
                    {
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "SPD489 low dose range (40mg, 80mg, and 100mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once-daily for 4 weeks; then,\n100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;\nif able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 Low Dose Range"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "SPD489 high dose range (120mg, 140mg and 160mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once daily for 1 week; then\n120 mg capsule once-daily for 1 week, then,\n140 mg capsule once-daily for 2 weeks, then\n160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;\nif able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 High Dose Range"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Placebo: One capsule a day for 26 weeks", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1"
                                                    }, 
                                                    {
                                                        "@group_id": "O2"
                                                    }, 
                                                    {
                                                        "@group_id": "O3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "title": "Clinical Global Impression-Schizophrenia Severity of Illness (CGI-SCH-S) Scale"
                                }
                            ]
                        }, 
                        "population": "Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and week 26", 
                        "title": "Clinical Global Impression-Schizophrenia Severity of Illness (CGI-SCH-S) Scale", 
                        "type": "Secondary"
                    }, 
                    {
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "SPD489 low dose range (40mg, 80mg, and 100mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once-daily for 4 weeks; then,\n100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;\nif able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 Low Dose Range"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "SPD489 high dose range (120mg, 140mg and 160mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once daily for 1 week; then\n120 mg capsule once-daily for 1 week, then,\n140 mg capsule once-daily for 2 weeks, then\n160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;\nif able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 High Dose Range"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Placebo: One capsule a day for 26 weeks", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1"
                                                    }, 
                                                    {
                                                        "@group_id": "O2"
                                                    }, 
                                                    {
                                                        "@group_id": "O3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "title": "Clinical Global Impression-Schizophrenia Degree of Change (CGI-SCH-C) Scale"
                                }
                            ]
                        }, 
                        "population": "Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized", 
                        "safety_issue": "No", 
                        "time_frame": "Up to 26 weeks", 
                        "title": "Clinical Global Impression-Schizophrenia Degree of Change (CGI-SCH-C) Scale", 
                        "type": "Secondary"
                    }, 
                    {
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "SPD489 low dose range (40mg, 80mg, and 100mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once-daily for 4 weeks; then,\n100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;\nif able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 Low Dose Range"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "SPD489 high dose range (120mg, 140mg and 160mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once daily for 1 week; then\n120 mg capsule once-daily for 1 week, then,\n140 mg capsule once-daily for 2 weeks, then\n160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;\nif able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 High Dose Range"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Placebo: One capsule a day for 26 weeks", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1"
                                                    }, 
                                                    {
                                                        "@group_id": "O2"
                                                    }, 
                                                    {
                                                        "@group_id": "O3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "title": "Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at 26 Weeks"
                                }
                            ]
                        }, 
                        "population": "Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized", 
                        "safety_issue": "Yes", 
                        "time_frame": "Baseline and 26 weeks", 
                        "title": "Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at 26 Weeks", 
                        "type": "Secondary"
                    }, 
                    {
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "SPD489 low dose range (40mg, 80mg, and 100mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once-daily for 4 weeks; then,\n100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;\nif able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 Low Dose Range"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "SPD489 high dose range (120mg, 140mg and 160mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once daily for 1 week; then\n120 mg capsule once-daily for 1 week, then,\n140 mg capsule once-daily for 2 weeks, then\n160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;\nif able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 High Dose Range"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Placebo: One capsule a day for 26 weeks", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1"
                                                    }, 
                                                    {
                                                        "@group_id": "O2"
                                                    }, 
                                                    {
                                                        "@group_id": "O3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "title": "Change From Baseline in Clinical Evaluation of Harmful Behavior (CEHB) Scale at 26 Weeks"
                                }
                            ]
                        }, 
                        "population": "Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized", 
                        "safety_issue": "Yes", 
                        "time_frame": "Baseline and 26 weeks", 
                        "title": "Change From Baseline in Clinical Evaluation of Harmful Behavior (CEHB) Scale at 26 Weeks", 
                        "type": "Secondary"
                    }, 
                    {
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "SPD489 low dose range (40mg, 80mg, and 100mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once-daily for 4 weeks; then,\n100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;\nif able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 Low Dose Range"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "SPD489 high dose range (120mg, 140mg and 160mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once daily for 1 week; then\n120 mg capsule once-daily for 1 week, then,\n140 mg capsule once-daily for 2 weeks, then\n160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;\nif able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 High Dose Range"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Placebo: One capsule a day for 26 weeks", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1"
                                                    }, 
                                                    {
                                                        "@group_id": "O2"
                                                    }, 
                                                    {
                                                        "@group_id": "O3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "title": "Columbia-Suicide Severity Rating Scale (C-SSRS)"
                                }
                            ]
                        }, 
                        "population": "Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized", 
                        "safety_issue": "Yes", 
                        "time_frame": "Up to 26 weeks", 
                        "title": "Columbia-Suicide Severity Rating Scale (C-SSRS)", 
                        "type": "Secondary"
                    }, 
                    {
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "SPD489 low dose range (40mg, 80mg, and 100mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once-daily for 4 weeks; then,\n100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;\nif able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 Low Dose Range"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "SPD489 high dose range (120mg, 140mg and 160mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once daily for 1 week; then\n120 mg capsule once-daily for 1 week, then,\n140 mg capsule once-daily for 2 weeks, then\n160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;\nif able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks", 
                                    "title": "SPD489 High Dose Range"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Placebo: One capsule a day for 26 weeks", 
                                    "title": "Placebo"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1"
                                                    }, 
                                                    {
                                                        "@group_id": "O2"
                                                    }, 
                                                    {
                                                        "@group_id": "O3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "title": "Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at 26 Weeks"
                                }
                            ]
                        }, 
                        "population": "Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized", 
                        "safety_issue": "Yes", 
                        "time_frame": "Baseline and 26 weeks", 
                        "title": "Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at 26 Weeks", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "P1", 
                            "description": "SPD489 low dose range (40mg, 80mg, and 100mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once-daily for 4 weeks; then,\n100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;\nif able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks", 
                            "title": "SPD489 Low Dose Range"
                        }, 
                        {
                            "@group_id": "P2", 
                            "description": "SPD489 high dose range (120mg, 140mg and 160mg): Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once daily for 1 week; then\n120 mg capsule once-daily for 1 week, then,\n140 mg capsule once-daily for 2 weeks, then\n160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;\nif able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks", 
                            "title": "SPD489 High Dose Range"
                        }, 
                        {
                            "@group_id": "P3", 
                            "description": "Placebo: One capsule a day for 26 weeks", 
                            "title": "Placebo"
                        }
                    ]
                }, 
                "period_list": {
                    "period": {
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "0", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "0", 
                                                "@group_id": "P2"
                                            }, 
                                            {
                                                "@count": "0", 
                                                "@group_id": "P3"
                                            }
                                        ]
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "0", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "0", 
                                                "@group_id": "P2"
                                            }, 
                                            {
                                                "@count": "0", 
                                                "@group_id": "P3"
                                            }
                                        ]
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "0", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "0", 
                                                "@group_id": "P2"
                                            }, 
                                            {
                                                "@count": "0", 
                                                "@group_id": "P3"
                                            }
                                        ]
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }, 
                "pre_assignment_details": "Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized"
            }, 
            "point_of_contact": {
                "name_or_title": "Study Physician", 
                "organization": "Shire", 
                "phone": "+1 866 842 5335"
            }
        }, 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  - 18 to 65 years of age\n\n          -  Has a reliable  informant (eg, family member, social worker, caseworker, or nurse\n             that spends >4 hours/week with the subject)\n\n          -  Fixed home/place of residence and can be reached by telephone\n\n          -  On a stable dose of antipsychotic medications\n\n          -  Able to swallow capsules\n\n        Exclusion Criteria:\n\n          -  Taking lithium, carbamazepine, lamotrigine, gabapentin, cholinesterase inhibitors,\n             modafinil, or other stimulants such as methylphenidate and other amphetamine products\n\n          -  Treated with clozapine in past 30 days\n\n          -  Lifetime history of stimulant, cocaine, or amphetamine abuse or dependence\n\n          -  History of seizures (other than infantile febrile seizures), any tic disorder, or\n             current diagnosis and/or a known family history of Tourette's Disorder, serious\n             neurological disease, history of significant head trauma, dementia, cerebrovascular\n             disease, Parkinson's disease, or intracranial lesions\n\n          -  Uncontrolled hypertension\n\n          -  History of thyroid disorder that has not been stabilized on thyroid medication\n\n          -  Glaucoma\n\n          -  Pregnant or nursing\n\n          -  Subject has received an investigational product or participated in a clinical study\n             within 30 days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 2, 2013", 
        "firstreceived_results_date": "May 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01760889", 
            "org_study_id": "SPD489-335", 
            "secondary_id": "2012-003919-57"
        }, 
        "intervention": [
            {
                "arm_group_label": "SPD489 Low Dose Range", 
                "description": "Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once-daily for 4 weeks; then,\n100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;\nif able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks", 
                "intervention_name": "SPD489 low dose range (40mg, 80mg, and 100mg)", 
                "intervention_type": "Drug", 
                "other_name": "lisdexamfetamine dimesylate, LDX, Vyvanse"
            }, 
            {
                "arm_group_label": "SPD489 High Dose Range", 
                "description": "Capsule, dose titration,\n40 mg capsule once-daily for 1 week; then\n80 mg capsule once daily for 1 week; then\n120 mg capsule once-daily for 1 week, then,\n140 mg capsule once-daily for 2 weeks, then\n160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;\nif able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks", 
                "intervention_name": "SPD489 high dose range (120mg, 140mg and 160mg)", 
                "intervention_type": "Drug", 
                "other_name": "lisdexamfetamine dimesylate, LDX, Vyvanse"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "One capsule a day for 26 weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antipsychotic Agents", 
                "Dextroamphetamine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 1, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami Springs", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33166"
                    }, 
                    "name": "Galiz Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "O'Fallon", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63368"
                    }, 
                    "name": "Psychiatric Care and Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Charles", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63304"
                    }, 
                    "name": "St. Charles Psychiatric Associates"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19139"
                    }, 
                    "name": "CRI Lifetree"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, 26-week, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 Low Dose Range (40mg, 80mg, 100mg) and High Dose Range (120mg, 140mg, 160mg) as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia", 
        "overall_official": {
            "affiliation": "Desert Pacific Mental Illness Research Education and Clinical Center Semel Institute for Neuroscience at UCLA", 
            "last_name": "Stephen R. Marder, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change From Baseline in Negative Symptom Assessment (NSA-16) Total Score at 26 Weeks", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 26 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01760889"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change From Baseline in the Personal and Social Performance (PSP) Scale Score at 26 Weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 26 weeks"
            }, 
            {
                "measure": "Change From Baseline in Simpson Angus Scale (SAS) Total Score at 26 Weeks", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and 26 weeks"
            }, 
            {
                "measure": "Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at 26 Weeks", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and 26 weeks"
            }, 
            {
                "measure": "Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) at 26 Weeks", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and 26 weeks"
            }, 
            {
                "measure": "Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at 26 Weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 26 weeks"
            }, 
            {
                "measure": "Change From Baseline in Cognitive Test Battery (CogState Battery) Score at 26 Weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 26 weeks"
            }, 
            {
                "measure": "Change From Baseline in Social Functioning Scale (SFS) at 26 Weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 26 weeks"
            }, 
            {
                "measure": "Clinical Global Impression-Schizophrenia Severity of Illness (CGI-SCH-S) Scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline and week 26"
            }, 
            {
                "measure": "Clinical Global Impression-Schizophrenia Degree of Change (CGI-SCH-C) Scale", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "measure": "Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at 26 Weeks", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and 26 weeks"
            }, 
            {
                "measure": "Change From Baseline in Clinical Evaluation of Harmful Behavior (CEHB) Scale at 26 Weeks", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and 26 weeks"
            }, 
            {
                "measure": "Columbia-Suicide Severity Rating Scale (C-SSRS)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "measure": "Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at 26 Weeks", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and 26 weeks"
            }
        ], 
        "source": "Shire", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shire", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014", 
        "why_stopped": "Study was discontinued due to non-safety related business prioritization decisions. No\n    subjects were randomized"
    }
}